This clinical trial is focused on studying the condition known as hypercholesterolemia, which is a medical term for having high levels of cholesterol in the blood. The trial will use a treatment called MK-0616, which is a film-coated tablet containing the active substance enlicitide chloride. The purpose of the study is to evaluate the safety and tolerability of this treatment in adults who have already completed a previous trial involving MK-0616.

Participants in this study will continue to take the MK-0616 tablet as part of an open-label extension, meaning that both the participants and the researchers know what treatment is being administered. The study will monitor participants for any adverse events, which are any unwanted effects that may occur during the trial. Additionally, the study will assess changes in cholesterol levels, specifically looking at low-density lipoprotein cholesterol (LDL-C), which is often referred to as “bad” cholesterol, and other related markers.

The trial is designed to last for several years, allowing researchers to gather comprehensive data on the long-term effects of MK-0616. Participants will be regularly monitored to ensure their safety and to track the effectiveness of the treatment in managing their cholesterol levels. This study aims to provide valuable information on how well MK-0616 works and how safe it is for people with high cholesterol.